Aluminum Oxide Arsenic Trioxide Atropa Belladonna
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aluminum Oxide Arsenic Trioxide Atropa Belladonna
- Multi-ingredient Homeopathic Complex (25 Components): Insufficient Data for TxGNN Repurposing Analysis
Multi-ingredient Homeopathic Complex (25 Components): Insufficient Data for TxGNN Repurposing Analysis
One-Sentence Summary
This product is a 25-component homeopathic combination containing botanical extracts, minerals, and biological nosodes (including Echinacea, Arsenic Trioxide, Atropa Belladonna, and Measles Virus), with no registered indications on record. The TxGNN model was unable to generate any repurposing predictions for this candidate, as no DrugBank ID could be mapped and no original indication exists to anchor the analysis. With 0 clinical trials and 0 supporting publications identified in this pipeline, this candidate cannot proceed under the current framework.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No registered indication available |
| Predicted New Indication | Unable to generate — no DrugBank mapping |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This candidate is not a single molecular entity but a heterogeneous 25-component homeopathic mixture comprising:
- Botanical extracts: Echinacea angustifolia, Atropa belladonna, Goldenseal (Hydrastis canadensis), Matricaria recutita, Milk thistle, Taraxacum officinale, Chelidonium majus, Baptisia tinctoria, Ledum palustre, Thuja occidentalis, Phytolacca americana, Peumus boldus
- Minerals / inorganics: Aluminum oxide, Arsenic trioxide, Silicon dioxide, Sulfur, Mercurius solubilis, Oyster shell calcium carbonate
- Biological nosodes: Human sputum (Bordetella pertussis-infected), Measles virus, Thyroid (unspecified), Rancid beef, Egg phospholipids
- Plant spores: Lycopodium clavatum, Toxicodendron pubescens
The TxGNN knowledge graph operates on discrete drug nodes identified by DrugBank IDs. Because this product has no DrugBank ID (drugbank_id: null) and cannot be mapped to any single pharmacological entity in the knowledge graph, the model returned zero predictions. This is expected behavior, not a pipeline failure.
Additionally, because the product is not marketed in any jurisdiction covered by this system (Taiwan FDA: 未上市, NDA count: 0), there is no regulatory anchor for original indication inference.
Safety Considerations
Please refer to the package insert for safety information.
Note on Arsenic Trioxide: When present as a conventional pharmaceutical agent (e.g., Trisenox®), arsenic trioxide carries black box warnings for QT prolongation, APL differentiation syndrome, and cardiomyopathy. If this product is intended for non-homeopathic use at pharmacological doses, safety review must begin with arsenic trioxide labeling requirements.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is a multi-ingredient homeopathic complex that cannot be represented as a single node in the TxGNN knowledge graph, producing zero repurposing predictions. Without a DrugBank ID, original indication, or any regulatory approval, the standard repurposing evaluation pipeline cannot proceed.
To proceed, the following is needed:
- Identity clarification: Determine whether this is a registered homeopathic product with an NHN/NDC number; if so, retrieve the product monograph to confirm intended indication and ingredient dilutions
- Component-level analysis: If the intent is to evaluate a specific active ingredient (e.g., Arsenic trioxide as a conventional oncology agent), submit that single INN as a separate candidate with its own DrugBank ID
- DrugBank mapping: Resolve
drugbank_id: null— attempt mapping via individual ingredient names or product-level registry cross-reference - MOA documentation (Data Gap DG002): Without mechanism of action data, mechanistic plausibility for any indication cannot be assessed
- Regulatory review (Data Gap DG001): TFDA package insert or equivalent labeling must be located before any safety evaluation can begin
- Scope decision: Clarify whether the goal is to evaluate the mixture as a whole or individual components — these require fundamentally different analytical frameworks
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.